Vaccine Development.
Anthrax
COVID-19
Ebola
Emerging infections
Influenza
Mpox
Pediatric vaccines
Smallpox
Journal
Pediatric clinics of North America
ISSN: 1557-8240
Titre abrégé: Pediatr Clin North Am
Pays: United States
ID NLM: 0401126
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
16
5
2024
Statut:
ppublish
Résumé
This article considers ethical considerations surrounding pediatric vaccine development for pandemic preparedness, examines some historical cases of pediatric vaccines developed during past smallpox, influenza, and 2019 coronavirus disease pandemics, and discusses the current state of vaccine development for pandemic preparedness, including vaccines against smallpox/mpox, influenza, anthrax, and Ebola that are included in the US Strategic National Stockpile and vaccines being developed against priority pathogens identified by the World Health Organization.
Identifiants
pubmed: 38754940
pii: S0031-3955(24)00029-4
doi: 10.1016/j.pcl.2024.01.018
pii:
doi:
Types de publication
Journal Article
Review
Historical Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-549Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures E.A. Hammershaimb and J.D. Campbell are investigators on clinical trials of COVID-19 vaccines developed by Moderna and Novavax and of an anthrax vaccine developed by Emergent. Their institution receives funds for the conduct of these trials; the authors have no direct financial interests in any of these companies.